Centre de Lutte contre le Cancer - François Baclesse

Caen 14076

0 studies enrolling now · 2 studies all time

What they study most

Carcinoma, Transitional Cell, HER2 Positive Breast Cancer

Studies at this site

• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma — Completed